Standard Contracts
Convertible Securities Purchase Agreement between engage:BDR Limited ACN 621 160 585 (Company) and Alto Opportunity Master Fund SPC – Segregated Master Portfolio B (Investor) and Engage BDR LLC (US Subsidiary)Convertible Securities Purchase Agreement • April 8th, 2021 • Engage BDR LTD • Services-advertising • Victoria
and Alto Opportunity Master Fund SPC – Segregated Master Portfolio B of c/- Ayrton Capital LLC, 1180 Avenue of Americas, Suite 842, New York, NY 10036 (Investor)
FORM OF CONVERTIBLE SECURITIES PURCHASE AGREEMENTConvertible Securities Purchase Agreement • August 6th, 2024 • Adagio Medical Holdings, Inc. • Surgical & medical instruments & apparatus • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February [●], 2024 (the “Subscription Date”), is by and among Aja Holdco, Inc., a Delaware corporation with offices located at 51 Astor Place, 10th Floor, New York, New York 10003 (the “Company”), ARYA Sciences Acquisition Corp IV, a company organized under the laws of the Cayman Islands with offices located at 51 Astor Place, 10th Floor, New York, New York 10003 (the “SPAC”), Adagio Medical, Inc., a Delaware corporation with offices located at 26051 Merit Circle, Suite 102, Laguna Hills, CA 92653 (the “Target” and together with the Company and the SPAC, the “BC Parties”), and each of the investors listed on the Schedule of Buyers attached hereto (each individually, a “Buyer” and collectively, the “Buyers”).
AMENDMENT TO CONVERTIBLE SECURITIES PURCHASE AGREEMENTConvertible Securities Purchase Agreement • October 26th, 2022 • British Columbia
SECOND AMENDMENT TO THE CONVERTIBLE SECURITIES PURCHASE AGREEMENTConvertible Securities Purchase Agreement • February 23rd, 2024 • British Columbia
CONVERTIBLE SECURITIES PURCHASE AGREEMENTConvertible Securities Purchase Agreement • August 14th, 2015 • Q Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Convertible Securities Purchase Agreement, dated as of June , 2015 (this “Agreement”), is entered into by and among Q Therapeutics, Inc. (the “Company”), a corporation incorporated in the state of Delaware, and the persons and entities listed on the schedule of investors attached hereto as Schedule I (the “Investors”).
CONVERTIBLE SECURITIES PURCHASE AGREEMENTConvertible Securities Purchase Agreement • March 24th, 2021 • Colorado
WHEREAS, subject to the terms and conditions of this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations promulgated thereunder, including Regulation D (“Regulation D”), the Purchaser desires to purchase, and the Company desires to issue and sell, ( ) shares (the “Preferred Shares”) of the Company’s Series A Convertible Preferred Stock, par value $5.00 per share (the “Preferred Stock”).
